Tigecycline for Treatment of Rapidly Growing Mycobacteria
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients
with rapidly growing mycobacterial disease (especially M.abscessus).
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at Tyler